Lady Image

“I know I can’t eliminate risk, but after speaking with my doctor about GLIVEC, I’m glad we have a plan in place that can help my chances of living recurrence free.”1

Successfully resected patients may be convinced they are cancer free. They need to know:

  • GIST has malignant potential, even after resection2,3
  • The National Comprehensive Cancer Network® (NCCN®) and the European Society for Medical Oncology (ESMO) recommend at least 36 months of imatinib therapy following resection in patients with a significant risk of recurrence3,5*
  • Adjuvant therapy with GLIVEC can significantly lower the risk of tumour recurrence1,6

Models are used for illustrative purposes only throughout the site. Patient quotes are intended for guidance only and do not reflect actual patient testimonials.

*The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend use in intermediate-risk and high-risk KIT+ GIST, whereas ESMO guidelines suggest use in high-risk patients.

*The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend use in intermediate-risk and high-risk KIT+ GIST, whereas ESMO guidelines suggest use in high-risk patients.

References: 1. Glivec® (imatinib) summary of product characteristics. Dublin, Ireland: Novartis Europharm Limited. 2. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459-465. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.2.2016. © National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed September 21, 2016. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 4. Sutent® (sunitinib malate) summary of product characteristics. Sandwich, Kent, UK: Pfizer Ltd. 5. The ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):ii21-ii-26. 6. DeMatteo RP, Ballman KV, Antonescu CR, et al; for the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097-1104.